Health Care·Biotechnology·$5.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.52 | N/A | -35.26% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.52 | N/A | -35.26% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current performance but remains focused on long-term goals. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
No specific updates were provided regarding future product launches.
The earnings report indicates that TG Therapeutics is facing challenges, particularly reflected in their EPS miss. The stock reacted negatively, declining by 0.99%, likely due to investor concerns about the lack of revenue updates and future guidance. Without clear direction from management, investors may remain cautious in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MERCK & CO. INC.
May 2, 2017